NBMI Treatment in Patients With Mercury Toxicity

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

November 22, 2023

Primary Completion Date

May 22, 2024

Study Completion Date

November 22, 2024

Conditions
Mercury Poisoning
Interventions
DRUG

(N1, N3-bis(2- mercaptoethyl)isophthalamide)

600mg / day NBMI treatment for 14 days, administered as four capsules of 100 mg of NBMI every 24 hours, at the start of treatment, the principal investigator or his delegate will verify the intake of the first dose and deliver a blister pack corresponding to the remaining NBMI capsules, at visit day 14 research subjects will be asked to return the packaging with the remaining capsules or not, in order to estimate adherence to treatment.

OTHER

Excipients microcrystalline cellulose, silica and magnesium stearate

6 Capsules will be administered every 24 hours for 14 days.

Trial Locations (1)

Unknown

RECRUITING

Clínica de la Costa Ltda., Barranquilla

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EmeraMed

INDUSTRY

NCT04183595 - NBMI Treatment in Patients With Mercury Toxicity | Biotech Hunter | Biotech Hunter